Loading...
Loading...
Loading...
Loading...
Powered by
Share
Supported by
Affiliations
Developed Francesc Català Moll and Marc Noguera i Julian
Contact us at covidseq@irsicaixa.es
Amb el suport de la Fundació La Marató de TV3 (Projecte 202126-30-21)
GISAID data provided on this website are a subject to GISAID's Terms and Conditions
Data from GISAID Initiative. Note, that it is important not to assume that shown data are necessarily representative of the all region due to a potential non uniform sampling.
Loading...
per 1e5 inhabitant correction
Loading...
Powered by
Share
Supported by
Affiliations
Developed Francesc Català Moll and Marc Noguera i Julian
Contact us at covidseq@irsicaixa.es
Amb el suport de la Fundació La Marató de TV3 (Projecte 202126-30-21)
GISAID data provided on this website are a subject to GISAID's Terms and Conditions
Notes for a correct interpretation
• Sampling may not be uniform within the different
autonomous communities. Therefore, it is important not
to assume that the counts/frequencies shown are
necessarily representative of the region.
• The charts used are based on the sample collection date,
and sequencing or GISAID submission date. As a result,
this date may differ from when the sample was processed
and sequenced, and when the data is released to the public.
• In relation with the last consideration, last data
points often has incomplete data and may change as more
sequences come in.
• The mutations that define SARS-CoV-2 (CoV-19) lineages
are updated every few days. Therefore, displayed data is
susceptible to change over time.
Acknowledgements
We are grateful to the data contributors who shared the
data used in this Web Application via the GISAID
Initia-tive*: the Authors, the Originating Laboratories
responsible for obtaining the specimens, and the Submitting
Laboratories that generated the genetic sequences and metadata.
* (a) Elbe, S., and Buckland-Merrett, G. (2017) Data,
disease and diplomacy: GISAID’s innovative contribution
to global health. Global Challenges, 1:33-46.
DOI:
10.1002/gch2.1018
PMCID:
31565258
(b) Shu, Y., McCauley, J. (2017) GISAID: From vision
to reality. EuroSurveillance, 22(13) DOI:
10.2807/1560-7917.ES.2017.22.13.30494
PMCID:
PMC5388101
Notes for a correct interpretation
• Sampling may not be uniform within the different autonomous communities. Therefore, it is important not to assume that the counts/frequencies shown are necessarily representative of the region.
• The charts used are based on the sample collection date, and sequencing or GISAID submission date. As a result, this date may differ from when the sample was processed and sequenced, and when the data is released to the public.
• In relation with the last consideration, last data points often has incomplete data and may change as more sequences come in.
• The mutations that define SARS-CoV-2 (CoV-19) lineages are updated every few days. Therefore, displayed data is susceptible to change over time.
Acknowledgements
We are grateful to the data contributors who shared the data used in this Web Application via the GISAID Initia-tive*: the Authors, the Originating Laboratories responsible for obtaining the specimens, and the Submitting Laboratories that generated the genetic sequences and metadata.
* (a) Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID’s innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258 (b) Shu, Y., McCauley, J. (2017) GISAID: From vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101
Powered by
Share
Supported by
Affiliations